Quest Diagnostics (DGX) Research Coverage Started at Credit Suisse Group
Stock analysts at Credit Suisse Group assumed coverage on shares of Quest Diagnostics (NYSE:DGX) in a research note issued to investors on Friday, February 2nd, Marketbeat reports. The firm set a “neutral” rating and a $107.00 price target on the medical research company’s stock. Credit Suisse Group’s price target suggests a potential upside of 10.97% from the company’s previous close.
Other equities research analysts have also issued reports about the company. Craig Hallum reiterated a “hold” rating and issued a $100.00 price objective (down from $110.00) on shares of Quest Diagnostics in a research report on Tuesday, October 17th. Piper Jaffray Companies reiterated a “hold” rating and issued a $110.00 price objective on shares of Quest Diagnostics in a research report on Thursday, February 1st. SunTrust Banks set a $105.00 target price on Quest Diagnostics and gave the company a “hold” rating in a research note on Sunday, October 15th. Mizuho set a $103.00 target price on Quest Diagnostics and gave the company a “buy” rating in a research note on Thursday, October 19th. Finally, Goldman Sachs Group began coverage on Quest Diagnostics in a research note on Monday, January 29th. They issued a “buy” rating and a $117.00 target price for the company. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $107.40.
Shares of Quest Diagnostics (NYSE:DGX) opened at $96.42 on Friday. The firm has a market capitalization of $13,140.00, a P/E ratio of 17.53, a PEG ratio of 1.84 and a beta of 0.67. Quest Diagnostics has a 1 year low of $90.10 and a 1 year high of $112.96. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.24 and a quick ratio of 1.15.
In other Quest Diagnostics news, Chairman Stephen H. Rusckowski sold 106,840 shares of Quest Diagnostics stock in a transaction on Monday, January 29th. The stock was sold at an average price of $107.00, for a total transaction of $11,431,880.00. Following the completion of the transaction, the chairman now owns 272,956 shares in the company, valued at $29,206,292. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Catherine T. Doherty sold 21,294 shares of Quest Diagnostics stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $104.00, for a total value of $2,214,576.00. Following the transaction, the senior vice president now owns 90,709 shares of the company’s stock, valued at approximately $9,433,736. The disclosure for this sale can be found here. Insiders have sold 192,014 shares of company stock valued at $19,950,134 in the last quarter. 1.75% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the business. APG Asset Management N.V. raised its stake in Quest Diagnostics by 156.0% during the third quarter. APG Asset Management N.V. now owns 2,683,901 shares of the medical research company’s stock valued at $251,320,000 after buying an additional 1,635,700 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Quest Diagnostics by 29.1% in the fourth quarter. Victory Capital Management Inc. now owns 2,487,295 shares of the medical research company’s stock worth $244,974,000 after purchasing an additional 560,538 shares during the last quarter. Bessemer Group Inc. raised its stake in shares of Quest Diagnostics by 73.1% in the fourth quarter. Bessemer Group Inc. now owns 2,107,796 shares of the medical research company’s stock worth $207,596,000 after purchasing an additional 889,802 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Quest Diagnostics by 16.8% in the fourth quarter. American Century Companies Inc. now owns 2,039,110 shares of the medical research company’s stock worth $200,832,000 after purchasing an additional 293,611 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its stake in shares of Quest Diagnostics by 10.5% in the third quarter. Allianz Asset Management GmbH now owns 2,033,496 shares of the medical research company’s stock worth $190,417,000 after purchasing an additional 193,829 shares during the last quarter. Institutional investors and hedge funds own 89.17% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/credit-suisse-group-initiates-coverage-on-quest-diagnostics-dgx/1842219.html.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.